CN1827640A - 血管生成抑制多肽及其制备方法和应用 - Google Patents
血管生成抑制多肽及其制备方法和应用 Download PDFInfo
- Publication number
- CN1827640A CN1827640A CN 200610039298 CN200610039298A CN1827640A CN 1827640 A CN1827640 A CN 1827640A CN 200610039298 CN200610039298 CN 200610039298 CN 200610039298 A CN200610039298 A CN 200610039298A CN 1827640 A CN1827640 A CN 1827640A
- Authority
- CN
- China
- Prior art keywords
- gly
- ala
- arg
- phe
- cys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 25
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 19
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title abstract description 8
- 230000014399 negative regulation of angiogenesis Effects 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 10
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 10
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 9
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 8
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 210000003000 inclusion body Anatomy 0.000 claims description 6
- 230000009465 prokaryotic expression Effects 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 238000012408 PCR amplification Methods 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 230000008034 disappearance Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000008521 reorganization Effects 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 claims description 3
- 238000012300 Sequence Analysis Methods 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 238000004153 renaturation Methods 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- UIKLEGZPIOXFHJ-DLOVCJGASA-N Cys-Phe-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O UIKLEGZPIOXFHJ-DLOVCJGASA-N 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 30
- 150000001413 amino acids Chemical class 0.000 abstract description 29
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000007998 vessel formation Effects 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 108010079505 Endostatins Proteins 0.000 description 16
- 102400001047 Endostatin Human genes 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102400000068 Angiostatin Human genes 0.000 description 4
- 108010079709 Angiostatins Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000004862 vasculogenesis Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- SBVJJNJLFWSJOV-UBHSHLNASA-N Arg-Ala-Phe Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SBVJJNJLFWSJOV-UBHSHLNASA-N 0.000 description 1
- ZHCCYSDALWJITB-SRVKXCTJSA-N Cys-Phe-Cys Chemical compound N[C@@H](CS)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CS)C(O)=O ZHCCYSDALWJITB-SRVKXCTJSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000010046 negative regulation of endothelial cell proliferation Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 108010066925 sleep-promoting factor B Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100392982A CN100398557C (zh) | 2006-04-05 | 2006-04-05 | 血管生成抑制多肽及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100392982A CN100398557C (zh) | 2006-04-05 | 2006-04-05 | 血管生成抑制多肽及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1827640A true CN1827640A (zh) | 2006-09-06 |
CN100398557C CN100398557C (zh) | 2008-07-02 |
Family
ID=36946213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100392982A Active CN100398557C (zh) | 2006-04-05 | 2006-04-05 | 血管生成抑制多肽及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100398557C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102850443A (zh) * | 2011-12-27 | 2013-01-02 | 中国药科大学 | 整合素阻断剂多肽及其应用 |
CN104327169A (zh) * | 2014-10-08 | 2015-02-04 | 南京安吉生物科技有限公司 | 整合素阻断剂多肽及其在制备治疗新生血管性眼病药物中的应用 |
CN105713095A (zh) * | 2016-03-14 | 2016-06-29 | 南京安吉生物科技有限公司 | 一种多功能融合多肽及其制备方法和应用 |
US9879052B2 (en) | 2011-12-27 | 2018-01-30 | Hanmei Xu | Integrin-blocking polypeptides and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6653098B1 (en) * | 1998-02-23 | 2003-11-25 | G. D. Searle & Co. | Method of producing mouse and human endostatin |
WO2000067771A1 (en) * | 1999-05-06 | 2000-11-16 | The Burnham Institute | Antiangiogenic endostatin peptides, endostatin variants and methods of use |
US7078485B2 (en) * | 2002-12-05 | 2006-07-18 | Yantai Medgenn Ltd. | N-terminal modified recombinant human endostatin and its production |
US7470667B2 (en) * | 2002-12-05 | 2008-12-30 | Medgenn (Hong Kong) Ltd | Methods of treating cancer using a modified endostatin protein |
KR20070030159A (ko) * | 2003-08-29 | 2007-03-15 | 칠드런'즈 메디컬 센터 코포레이션 | 엔도스타틴의 n-말단으로부터의 항-혈관형성 펩티드 |
CN1328289C (zh) * | 2004-03-16 | 2007-07-25 | 哈尔滨医科大学 | 改变结构、增强抗肿瘤活性的内皮抑素及其制备 |
-
2006
- 2006-04-05 CN CNB2006100392982A patent/CN100398557C/zh active Active
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180103188A (ko) * | 2011-12-27 | 2018-09-18 | 한메이 쉬 | 인테그린 차단제 폴리펩타이드 및 그의 응용 |
WO2013097709A1 (zh) * | 2011-12-27 | 2013-07-04 | Xu Hanmei | 整合素阻断剂多肽及其应用 |
CN102850443B (zh) * | 2011-12-27 | 2014-04-16 | 中国药科大学 | 整合素阻断剂多肽及其应用 |
KR20140116447A (ko) * | 2011-12-27 | 2014-10-02 | 한메이 쉬 | 인테그린 차단제 폴리펩타이드 및 그의 응용 |
US20140316106A1 (en) * | 2011-12-27 | 2014-10-23 | Hanmei Xu | Integrin-blocking polypeptides and uses thereof |
KR102003422B1 (ko) * | 2011-12-27 | 2019-07-24 | 한메이 쉬 | 인테그린 차단제 폴리펩타이드 및 그의 응용 |
KR101966762B1 (ko) * | 2011-12-27 | 2019-04-09 | 한메이 쉬 | 인테그린 차단제 폴리펩타이드 및 그의 응용 |
US9458203B2 (en) * | 2011-12-27 | 2016-10-04 | Hanmei Xu | Integrin-blocking polypeptides and uses thereof |
AU2012361902B2 (en) * | 2011-12-27 | 2017-10-05 | Hanmei Xu | Integrin blocker polypeptide and use thereof |
CN102850443A (zh) * | 2011-12-27 | 2013-01-02 | 中国药科大学 | 整合素阻断剂多肽及其应用 |
US9879052B2 (en) | 2011-12-27 | 2018-01-30 | Hanmei Xu | Integrin-blocking polypeptides and uses thereof |
CN104327169B (zh) * | 2014-10-08 | 2017-12-26 | 南京安吉生物科技有限公司 | 整合素阻断剂多肽及其在制备治疗新生血管性眼病药物中的应用 |
CN104327169A (zh) * | 2014-10-08 | 2015-02-04 | 南京安吉生物科技有限公司 | 整合素阻断剂多肽及其在制备治疗新生血管性眼病药物中的应用 |
CN105713095A (zh) * | 2016-03-14 | 2016-06-29 | 南京安吉生物科技有限公司 | 一种多功能融合多肽及其制备方法和应用 |
CN105713095B (zh) * | 2016-03-14 | 2021-05-07 | 南京安吉生物科技有限公司 | 一种多功能融合多肽及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100398557C (zh) | 2008-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1163611C (zh) | 在棒状细菌中可自主复制的质粒 | |
CN101062952A (zh) | 由人血清白蛋白和干扰素组成的融合蛋白及其编码基因与应用 | |
CN1642570A (zh) | 含吸因子ⅷ的稳定药物组合物 | |
CN1861799A (zh) | 一种改进的重叠延伸pcr方法及其所获得的突变基因 | |
CN1313491C (zh) | 猫ω干扰素及其编码基因与应用 | |
CN1049166A (zh) | Magainin肽的取代类似物 | |
CN1958794A (zh) | 人肿瘤坏死因子相关凋亡诱导配体突变体编码cDNA及制备方法和应用 | |
CN1827640A (zh) | 血管生成抑制多肽及其制备方法和应用 | |
CN1778930A (zh) | 激发机体抗鸡球虫感染的融合基因及其编码蛋白与应用 | |
CN1846785A (zh) | 含有基因工程融合蛋白的冻干组合物 | |
CN1814761A (zh) | 吡咯喹啉醌合成相关基因及其编码蛋白 | |
CN1629194A (zh) | 一种可用以抗癌治疗的超抗原融合蛋白质及其生产方法 | |
CN1274829C (zh) | 抗eb病毒所致肿瘤多肽及其应用与制备方法 | |
CN1626554A (zh) | 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因 | |
CN1891718A (zh) | 融合免疫毒素ml-l-sec2和基因及其制备 | |
CN1840546A (zh) | 具有导向杀灭肿瘤细胞的重组融合蛋白 | |
CN1954882A (zh) | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 | |
CN1186448C (zh) | 重组人α胸腺素原-白介素2基因及其表达、应用 | |
CN1292002C (zh) | 一种精氨酸脱酰酶融合蛋白、其制造方法及应用 | |
CN1864746A (zh) | 幽门螺杆菌AhpC基因工程多价亚单位疫苗及其制备方法 | |
CN1274828C (zh) | 鼠源epor胞外区与人源nok胞内区嵌合受体及编码基因与应用 | |
CN1255186C (zh) | 人端粒酶反转录酶样组分的基因突变体的新用途 | |
CN1566159A (zh) | 一种能特异杀死肿瘤细胞的基因工程重组蛋白 | |
CN1798837A (zh) | 修饰的硫氧还蛋白 | |
CN101041690A (zh) | 重组犬钩虫抗凝肽5突变体、其编码基因、其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NANJING ANJI BIOLOGICAL SCIENCE + TECHNOLOGY CO., Free format text: FORMER OWNER: CHINA PHARMACEUTICAL UNIVERSITY Effective date: 20141102 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 210000 NANJING, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141102 Address after: 210000 Jiangsu city of Nanjing province Nanjing economic and Technological Development Zone Heng Road No. 8 Zijin branch base room 207 Patentee after: Nanjing Anji Biotechnology Co., Ltd. Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee before: China Pharmaceutical University |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Nanjing Anji Biotechnology Co., Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice |
Addressee: Nanjing Anji Biotechnology Co., Ltd. Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice |